Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:ATCCode |
none
|
| gptkbp:CASNumber |
1266084-52-4
|
| gptkbp:clinicalTrialPhase |
Phase II
|
| gptkbp:developedBy |
gptkb:Gilead_Sciences
|
| gptkbp:hasMolecularFormula |
C23H19F3N4O3S
|
| gptkbp:hasSMILES |
COC1=NC(=C(C(=N1)N2CCOCC2)C3=NC=C(C=C3)C(F)(F)F)C4=CC5=C(C=C4)OCCO5
|
| https://www.w3.org/2000/01/rdf-schema#label |
entospletinib
|
| gptkbp:intendedUse |
treatment of hematological malignancies
|
| gptkbp:isApprovedDrug |
true
|
| gptkbp:IUPACName |
5-(6-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-(trifluoromethyl)pyridin-3-yl)-2-methoxy-4-(morpholin-4-yl)pyrimidine
|
| gptkbp:mechanismOfAction |
Syk inhibitor
|
| gptkbp:molecularWeight |
488.5 g/mol
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL2105727
57379313 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:synonym |
GS-9973
GS9973 |
| gptkbp:target |
spleen tyrosine kinase (Syk)
|
| gptkbp:bfsParent |
gptkb:Syk
gptkb:Syk_kinase gptkb:Kronos_Bio |
| gptkbp:bfsLayer |
8
|